Market Overview

Cell Viability Assays Market, 2023

Share:

Cell Viability Assays Market, 2023

PR Newswire

DUBLIN, Sept. 13, 2018 /PRNewswire/ --

Research and Markets Logo. (PRNewsFoto/Research and Markets) (PRNewsfoto/Research and Markets)

The "Cell Viability Assays Market by Product (MTT Assay, XTT Assay, Calcein, Resazurin, Flow Cytometry, Spectrophotometer), Cell Type (Human, Animal, Microbial), Application (Basic Research, Stem Cell, Discovery & Development) - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

The global cell viability assays market is projected to reach USD 4.16 billion by 2023 from USD 2.78 billion in 2018, at a CAGR of 8.4%.

Factors contributing to the growth of this market include the rising incidence and prevalence of chronic and infectious diseases, growing availability of funds for research, rising demand for cell-based assays in research, and increasing focus on the development of cell-based therapeutics.

The report analyzes the global cell viability assays market by product, cell type, application, end user, and region. On the basis of product, the consumables segment is expected to account for the largest share of the market in 2018. The large share can be attributed to the repeated consumption of consumables in various cell viability procedures.

The growing focus on stem cell and cancer research is another major driver for the growth of the cell viability consumables market during the forecast period. In addition, the growing application of cell viability in quality control procedures in various industries such as food and beverage, pharmaceutical, biotechnology products manufacturing, and in the field of environmental monitoring and water treatment is also expected to play a key role in the growth of the cell viability consumables market during the forecast period.

Based on cell type, the human cells segment is expected to register the highest CAGR during the forecast period. This can be attributed to the growing investments by government bodies and private sector organizations in research activities that are focused on developing new treatments for various human diseases.

Based on application, the drug discovery & development application segment is expected to account for the largest share of the global cell viability assays market in 2018. The large share of this segment can be attributed to the rising incidence and prevalence of chronic and infectious diseases and increasing government support for developing new treatments for various human diseases.

Based on end user, the pharmaceutical and biotechnology companies segment is expected to register the highest CAGR during the forecast period. This can be attributed to the increasing number of R&D activities undertaken by these companies for the development of biopharmaceutical products.

Geographically, the global cell viability assays market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2018, North America is expected to account for the largest share of the cell viability assays market, followed by Europe and Asia Pacific.

The dominance of the North American region can be attributed to the growing incidence of various infectious diseases, investment initiatives by the government, and the high-quality infrastructure for clinical and laboratory research. Various additional advantages such as the availability of insurance coverage for laboratory testing procedures, rising healthcare and R&D expenditure, and the presence of well-structured distribution channels in the region are also supporting the growth of the market.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights
4.1 Cell Viability Assays Market Overview
4.2 Cell Viability Assays Market: Geographic Overview (2017)
4.3 Regional Mix: Cell Viability Assays Market (2018-2023)
4.4 Asia Pacific: Cell Viability Assays Market, By End User & Country (2017)
4.5 Cell Viability Assays Market: Developed vs Developing Markets

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Rising Incidence and Prevalence of Chronic and Infectious Diseases
5.2.1.2 Growing Availability of Funds for Research
5.2.1.3 Rising Demand for Cell-Based Assays in Research
5.2.1.4 Increasing Focus on the Development of Cell-Based Therapeutics
5.2.2 Restraint
5.2.2.1 High Cost of Instruments
5.2.3 Opportunities
5.2.3.1 Emerging Markets
5.2.3.2 Growing Focus on Stem Cell Research

6 Cell Viability Assays Market, By Product
6.1 Introduction
6.2 Consumables
6.2.1 Reagents
6.2.2 Assay Kits
6.2.2.1 Tetrazolium Reduction Assay Kits
6.2.2.1.1 Mtt Assay Kits
6.2.2.1.2 Other Tetrazolium Assay Kits
6.2.2.2 Resazurin Cell Viability Assay Kits
6.2.2.3 Calcein-Am Cell Viability Assay Kits
6.2.2.4 Other Assay Kits
6.2.3 Microplates
6.3 Instruments
6.3.1 Automated Cell Counters
6.3.2 Flow Cytometers
6.3.3 Spectrophotometers
6.3.4 Cell Imaging & Analysis Systems

7 Cell Viability Assays Market, By Cell Type
7.1 Introduction
7.2 Human Cells
7.3 Animal Cells
7.4 Microbial Cells

8 Cell Viability Assays Market, By Application
8.1 Introduction
8.2 Drug Discovery and Development
8.3 Basic Research
8.4 Stem Cell Research
8.5 Clinical and Diagnostic Applications
8.6 Other Applications

9 Cell Viability Assays Market, By End User
9.1 Introduction
9.2 Pharmaceutical & Biotechnology Companies
9.3 Academic & Research Institutes
9.4 Hospital & Diagnostic Laboratories
9.5 Other End Users

10 Cell Viability Assays Market, By Region
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 UK
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Rest of Asia Pacific
10.5 Latin America
10.6 Middle East & Africa

11 Competitive Landscape
11.1 Overview
11.2 Market Share Analysis
11.2.1 Market Share Analysis: Cell Viability Assay Kits Market
11.3 Competitive Situation and Trends
11.3.1 Product Launches
11.3.2 Expansions
11.3.3 Acquisitions
11.3.4 Other Strategies

12 Company Profiles
12.1 Thermo Fisher Scientific
12.2 Merck KGaA
12.3 Bio-Rad Laboratories
12.4 GE Healthcare
12.5 Danaher Corporation
12.6 Becton, Dickinson and Company
12.7 Promega Corporation
12.8 Biotium
12.9 Abcam PLC
12.10 Creative Bioarray
12.11 Biotek Instruments
12.12 Perkinelmer

For more information about this report, visit

https://www.researchandmarkets.com/research/7xw6h2/cell_viability?w=5

Media Contact:




Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cell-viability-assays-market-2023-300712067.html

SOURCE Research and Markets

View Comments and Join the Discussion!